Gilead Sciences News

Over his 28 years, Burrill's clients have included Steve Jobs of Apple, Genentech, Amgen and Gilead Sciences.

Based on the aggregated intelligence of 140,000-plus investors participating in Motley Fool CAPS , the Fool's free investing community, biotech giant Gilead Sciences has earned a coveted five-star ranking .

David Gardner called it. Hea TMs up 1,334%! See what Davida TMs recommending that you buy NEXT.

Filed under: Market matters , Abbott Laboratories , Aetna Inc , CIGNA Corp , Gilead Sciences , Stocks to Buy , Cramer on BloggingStocks TheStreet.com's Jim Cramer says the Senate is filled with more-savvy politicians, and the upside for beaten-down names is huge.

FreeBalance , a leading global provider of software solutions for public financial management, is pleased to announce the results of its most recent internal audit which show a dramatic increase in the size and scope of FreeBalance Government Resource Planning software implementations worldwide since 2006.

GS 9191 is an anti-proliferative agent that works by inhibiting cellular DNA synthesis, leading to the induction of apoptosis, or programmed cell death.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 11/04/09, Genta Incorporated announced the Company will release its third quarter 2009 financial results on Monday, November 16, 2009.

The drug industry's response to the HIV epidemic is widely viewed as a story of sterling R&D success.

A complete list of all headlines and biomedical stock developments can be found on BioMedReports.Com On 10/30/09, Gilead Sciences, Inc.

Long-term Studies Show Tenofovir Safety and Efficacy Is Sustained at 3 Years in HBeAg Positive and Negative Hepatitis B Patients SUMMARY: Long-term follow-up data from 2 clinical trials show that tenofovir remained active against hepatitis B virus and was generally well-tolerated for up to 3 years, researchers reported this past weekend at the 60th ...

A bad week for stocks has investors worried. But one top-performing letter remains fully invested.

Gilead Sciences, Inc. today announced the presentation of three-year open label data from two pivotal Phase III clinical trials, Studies 102 and 103, evaluating the safety and efficacy of once-daily Viread among adult patients with chronic hepatitis B virus infection.

Last October, in the heart of the financial crisis, The Motley Fool launched the Motley Fool Pro service.

Stocks discussed on the lightning round s ession of Jim Cramer's Mad Money TV Program, Tuesday October 27.

Main Category: Infectious Diseases / Bacteria / Viruses Also Included In: Regulatory Affairs / Drug Approvals Article Date: 28 Oct 2009 Gilead Sciences, Inc.

InvestorSoup.com announces an investment report featuring Inovio Biomedical Corp.

Gilead Sciences, Inc. today announced that aztreonam for inhalation solution, an investigational product for the treatment of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis , is scheduled to be reviewed by the Anti-Infective Drugs Advisory Committee of the U.S. Food and Drug Administration on December 10, 2009.

HUNTINGTON BEACH, Calif.-- --Llorente SIU, in partnership with Alaska National Insurance Company, learned today of the arrest of a Huntington Park man for alleged workers' compensa... NEWARK, Del.-- --PicksThatMove is pleased to bring investors special situation stocks which have a high potential for price appreciation.

SLM Corp., otherwise known as Sallie Mae, reported a 40% gain in net earnings for the third quarter.

Yesterday we told you that Google tops the list of heavyweight stocks in terms of "market capitalization per employee." There's $8.6 million in stock-market value riding on every Googler who works for the company.